Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (18193)	10/29/2005 11:15:50 PM
From: DewDiligence_on_SI	Respond to of 52153

SEPR has been pushing for their single-isomer Norvasc plus an ARB, but doesn't seem like they have been able to get any of the 5 (if I recall correctly) ARB makers to bite. Forest would seem like a natural partner for them. Benicar is a good drug; however, to pursue a Benicar+single-isomer-Norvasc combo, SEPR ought to be talking to Sankyo. FRX is tied into promoting Benicar only until 2008, and they probably don’t have the right to do anything with a combo pill without Sankyo’s permission. Regards, Dew